Physician profile
Ramesh C Gupta
NPI 1205813391
$143,166.20
in general payments reported to CMS, 2019-2025
29 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $9,176 · 2021: $23K · 2022: $26K · 2023: $22K · 2024: $32K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Travel and Lodging: $5,642 · Food and Beverage: $4,805 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,470.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,925.00 |
| Travel and Lodging | $5,641.54 |
| Food and Beverage | $4,805.04 |
| Education | $105.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74,930.34 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $25,618.87 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $19,229.77 | 2019-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $16,338.16 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $5,345.37 | 2020-2021 | |
| Gilead Sciences, INC. | $274.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.34 | 2022-2023 | Zeposia |
| Pfizer INC. | $169.95 | 2019-2025 | |
| Ardelyx, INC. | $157.61 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $133.30 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $118.00 | 2022-2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $104.97 | 2019-2021 | |
| Exact Sciences Corporation | $65.77 | 2025 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $52.68 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $39.08 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.38 | 2025 | Wegovy |
| Evoke Pharma, INC. | $34.09 | 2023 | Gimoti |
| Braintree Laboratories, INC. | $30.97 | 2019-2021 | |
| Medtronic, INC. | $27.64 | 2021-2023 | Chameleon |
| Allergan, INC. | $26.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $25.89 | 2019-2024 | Rebyota |
| Shionogi INC | $25.10 | 2019 | |
| Endo Pharmaceuticals INC. | $24.85 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $22.39 | 2024 | Bylvay |
| Tetraphase Pharmaceuticals, INC. | $18.85 | 2020 | |
| Madrigal Pharmaceuticals | $18.60 | 2024 | Resmetirom |
| Alfasigma USA, INC. | $17.41 | 2020 | |
| Celltrion USA INC. | $16.33 | 2024 | Zymfentra |
| Vivus LLC | $15.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.